Prevalence, costs, and treatment of Alzheimer's disease and related dementia

A managed care perspective

D. P. Rice, H. M. Fillit, W. Max, David S Knopman, J. R. Lloyd, S. Duttagupta

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Background: The number of patients with Alzheimer's disease (AD) and related dementia treated in managed care organizations (MCOs) is increasing, and this trend is expected to continue. Therefore, it is critical that MCOs develop disease management strategies for this population. Objective: To review the literature on the prevalence, costs, and treatment of AD and related dementia. Study design: Review of published articles from MEDLINE and peer-reviewed journals. Results: Prevalence of AD and related dementia is approximately 5.7% among those aged 65 and older. Prevalence data from claims-based studies of AD in managed care are lower, ranging from 0.55% to 0.83%. Costs for formal care average $27,672 per patient annually, with long-term care being the most costly component. Annual costs for informal care are estimated to be $10,400 to $34,517 per patient. Additional costs associated with AD include lost wages and productivity of patients and caregivers and costs associated with increased morbidity of caregivers. Donepezil treatment is well tolerated and has been extensively tested and evaluated in clinical settings. Early diagnosis and treatment of AD with donepezil has been shown to slow cognitive decline in AD. Although study findings regarding the cost offsets of donepezil-treated patients to date are mixed, there is a growing body of evidence to support the inclusion of this and other therapies into an MCO's AD treatment armamentarium. Conclusions: It is unlikely that MCOs will escape the increased prevalence and costs associated with AD. Opportunities exist through patient management programs targeted toward early diagnosis, effective use of medications, control of comorbidities, and patient and family support to partially offset these costs while providing quality patient care.

Original languageEnglish (US)
Pages (from-to)809-818
Number of pages10
JournalAmerican Journal of Managed Care
Volume7
Issue number8
StatePublished - 2001
Externally publishedYes

Fingerprint

Managed Care Programs
dementia
managed care
Health Care Costs
Dementia
Alzheimer Disease
costs
Costs and Cost Analysis
Organizations
early diagnosis
Caregivers
Early Diagnosis
Patient Care
caregiver
Quality of Health Care
Salaries and Fringe Benefits
Long-Term Care
Therapeutics
Critical Care
Disease Management

ASJC Scopus subject areas

  • Nursing(all)
  • Medicine(all)
  • Health(social science)
  • Health Professions(all)

Cite this

Prevalence, costs, and treatment of Alzheimer's disease and related dementia : A managed care perspective. / Rice, D. P.; Fillit, H. M.; Max, W.; Knopman, David S; Lloyd, J. R.; Duttagupta, S.

In: American Journal of Managed Care, Vol. 7, No. 8, 2001, p. 809-818.

Research output: Contribution to journalArticle

Rice, D. P. ; Fillit, H. M. ; Max, W. ; Knopman, David S ; Lloyd, J. R. ; Duttagupta, S. / Prevalence, costs, and treatment of Alzheimer's disease and related dementia : A managed care perspective. In: American Journal of Managed Care. 2001 ; Vol. 7, No. 8. pp. 809-818.
@article{ecc19e3c381641a3a67fc6b2e20c7b03,
title = "Prevalence, costs, and treatment of Alzheimer's disease and related dementia: A managed care perspective",
abstract = "Background: The number of patients with Alzheimer's disease (AD) and related dementia treated in managed care organizations (MCOs) is increasing, and this trend is expected to continue. Therefore, it is critical that MCOs develop disease management strategies for this population. Objective: To review the literature on the prevalence, costs, and treatment of AD and related dementia. Study design: Review of published articles from MEDLINE and peer-reviewed journals. Results: Prevalence of AD and related dementia is approximately 5.7{\%} among those aged 65 and older. Prevalence data from claims-based studies of AD in managed care are lower, ranging from 0.55{\%} to 0.83{\%}. Costs for formal care average $27,672 per patient annually, with long-term care being the most costly component. Annual costs for informal care are estimated to be $10,400 to $34,517 per patient. Additional costs associated with AD include lost wages and productivity of patients and caregivers and costs associated with increased morbidity of caregivers. Donepezil treatment is well tolerated and has been extensively tested and evaluated in clinical settings. Early diagnosis and treatment of AD with donepezil has been shown to slow cognitive decline in AD. Although study findings regarding the cost offsets of donepezil-treated patients to date are mixed, there is a growing body of evidence to support the inclusion of this and other therapies into an MCO's AD treatment armamentarium. Conclusions: It is unlikely that MCOs will escape the increased prevalence and costs associated with AD. Opportunities exist through patient management programs targeted toward early diagnosis, effective use of medications, control of comorbidities, and patient and family support to partially offset these costs while providing quality patient care.",
author = "Rice, {D. P.} and Fillit, {H. M.} and W. Max and Knopman, {David S} and Lloyd, {J. R.} and S. Duttagupta",
year = "2001",
language = "English (US)",
volume = "7",
pages = "809--818",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "8",

}

TY - JOUR

T1 - Prevalence, costs, and treatment of Alzheimer's disease and related dementia

T2 - A managed care perspective

AU - Rice, D. P.

AU - Fillit, H. M.

AU - Max, W.

AU - Knopman, David S

AU - Lloyd, J. R.

AU - Duttagupta, S.

PY - 2001

Y1 - 2001

N2 - Background: The number of patients with Alzheimer's disease (AD) and related dementia treated in managed care organizations (MCOs) is increasing, and this trend is expected to continue. Therefore, it is critical that MCOs develop disease management strategies for this population. Objective: To review the literature on the prevalence, costs, and treatment of AD and related dementia. Study design: Review of published articles from MEDLINE and peer-reviewed journals. Results: Prevalence of AD and related dementia is approximately 5.7% among those aged 65 and older. Prevalence data from claims-based studies of AD in managed care are lower, ranging from 0.55% to 0.83%. Costs for formal care average $27,672 per patient annually, with long-term care being the most costly component. Annual costs for informal care are estimated to be $10,400 to $34,517 per patient. Additional costs associated with AD include lost wages and productivity of patients and caregivers and costs associated with increased morbidity of caregivers. Donepezil treatment is well tolerated and has been extensively tested and evaluated in clinical settings. Early diagnosis and treatment of AD with donepezil has been shown to slow cognitive decline in AD. Although study findings regarding the cost offsets of donepezil-treated patients to date are mixed, there is a growing body of evidence to support the inclusion of this and other therapies into an MCO's AD treatment armamentarium. Conclusions: It is unlikely that MCOs will escape the increased prevalence and costs associated with AD. Opportunities exist through patient management programs targeted toward early diagnosis, effective use of medications, control of comorbidities, and patient and family support to partially offset these costs while providing quality patient care.

AB - Background: The number of patients with Alzheimer's disease (AD) and related dementia treated in managed care organizations (MCOs) is increasing, and this trend is expected to continue. Therefore, it is critical that MCOs develop disease management strategies for this population. Objective: To review the literature on the prevalence, costs, and treatment of AD and related dementia. Study design: Review of published articles from MEDLINE and peer-reviewed journals. Results: Prevalence of AD and related dementia is approximately 5.7% among those aged 65 and older. Prevalence data from claims-based studies of AD in managed care are lower, ranging from 0.55% to 0.83%. Costs for formal care average $27,672 per patient annually, with long-term care being the most costly component. Annual costs for informal care are estimated to be $10,400 to $34,517 per patient. Additional costs associated with AD include lost wages and productivity of patients and caregivers and costs associated with increased morbidity of caregivers. Donepezil treatment is well tolerated and has been extensively tested and evaluated in clinical settings. Early diagnosis and treatment of AD with donepezil has been shown to slow cognitive decline in AD. Although study findings regarding the cost offsets of donepezil-treated patients to date are mixed, there is a growing body of evidence to support the inclusion of this and other therapies into an MCO's AD treatment armamentarium. Conclusions: It is unlikely that MCOs will escape the increased prevalence and costs associated with AD. Opportunities exist through patient management programs targeted toward early diagnosis, effective use of medications, control of comorbidities, and patient and family support to partially offset these costs while providing quality patient care.

UR - http://www.scopus.com/inward/record.url?scp=0034861814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034861814&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 809

EP - 818

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 8

ER -